应用SELDI-TOF-MS技术建立肝癌筛选血清蛋白质指纹图谱模型

目的:建立肝癌筛选血清蛋白质指纹图谱模型．方法:用表面加强激光解析电离飞行时间质谱技术(SELDI-TOF-MS)及WCX2蛋白芯片获得新发肝癌、肝硬化患者和正常人血清的蛋白质指纹图谱,用计算机软件进行比较分析,建立肝癌的筛选模型．结果:肝癌患者与健康对照组血清蛋白质指纹图谱之间有5个标志蛋白(4477,8943,5181, 8617,13 761 Da)在肝癌患者血清中高表达,肝癌患者与肝硬化患者血清蛋白质指纹图谱之间2个标志蛋白(4477,13 761 Da)在肝癌患者血清中高表达,1个标志蛋白(4097 Da)在肝癌患者血清中低表达．SELDI-TOF-MS技术的特异性(60／60,100％);敏感度(18／20,90％)．分析系统筛选出4477,8943,13 761,4097 Da标志蛋白建立的肝癌诊断模型．结论:建立的血清蛋白质指纹图谱模型能够区分肝癌与非肝癌患者,SELDI-TOF-MS在肝癌的诊断及肿瘤特异性蛋白质生物标志分子的筛选等方面具有一定价值．

Establishment of serum protein pattern model for screening hepatocellular carcinoma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

AIM: To establish a serum protein pattern model for screening hepatic cellular carcinoma. METHODS: The proteomic spectra of patients with hepatic cellular carcinoma, hepatic cirrhosis, and healthy people were obtained by surface-enhanced laser desorption/ionization timeof-flight mass spectrometry (SELDI-TOF-MS) on WCX2 chips. The collected data were compared and analyzed by Biomarker Wizard software. RESULTS: A group of proteomic peaks were detected. The expression of five protein molecules (4477, 8943, 5181, 8617, 13 761 Da) in patients with hepatic cellular carcinoma was significantly higher than those in the controls, and the expression of 4477- and 13 761-Da proteins were higher while the 4097-Da one was lower in HCC patients than cirrhosis ones. The specificity and sensitivity of SELDI-TOF-MS were 100% (60/60) and 90% (18/20), respectively. Four protein molecules (4477,8943,13 761,4097 Da) were screened as a proteomic model. CONCLUSION: The discovered serum protein pattern model can efficiently identify patients with or without hepatocellular carcinoma. SEL-DI-TOF-MS plays a valuable role in the diagnosis of hepatocellular carcinoma and the discovery of new tumor-specific protein biomarkers.